TG Therapeutics Inc (TGTX)

[stockguard]

Another small gap down to start the week. All stocks getting in on this correction.

Looking forward to this upcoming though:

TG Therapeutics, Inc. Highlights Schedule of Events at the Upcoming 34th Congress of ECTRIMS
Final ublituximab phase 2 Multiple Sclerosis data to be featured in an oral presentation, Thursday, October 11, 2018, 16:51-17:03 CEST

ECTRIMS data review conference call to be held Thursday, October 11, 2018, 19:30 CEST/1:30pm ET

NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of events featuring ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) at the upcoming 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held October 10 – 12, 2018, at City Cube in Berlin, Germany.

Final results from the Phase 2 trial of ublituximab in RMS patients will be presented via an oral presentation during the annual congress of ECTRIMS. Following the oral presentation, the Company will host a data review conference call during which Dr. Edward Fox, PhD, Director of the MS Clinic of Central Texas, Central Texas Neurology Consultants, PA, Clinical Associate Professor at the University of Texas Dell Medical School and the Principal Investigator for the Phase 2 trial, will review the data presented and will be available for questions. Additional details are provided below.

Oral Presentation Details:

Title: Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)
Presentation Date & Time:Thursday, October 11th, 2018; 16:51-17:03 CEST
Session Title: Free Communications 4 - Treatment
Location: City Cube, Berlin, Germany
Presenter: Edward Fox, MD, PhD, Director, MS Clinic of Central Texas, Central Texas Neurology Consultants, PA and Clinical Associate Professor at the University of Texas Dell Medical School
Following the presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.

Conference Call Details:

Title: TG Therapeutics ECTRIMS Data Review Call
Date & Time:Thursday, October 11th, 2018; 19:30 CEST/1:30pm ET
Dial in: 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.)
Webcast:http://ir.tgtherapeutics.com/events
Presenter:Edward Fox, MD, PhD, Director, MS Clinic of Central Texas, Central Texas Neurology Consultants, PA and Clinical Associate Professor at the University of Texas Dell Medical School
An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

These data support the ongoing international Phase 3 program evaluating ublituximab for the treatment of relapsing form of Multiple Sclerosis (RMS). The Phase 3 trials, entitled ULTIMATE I and ULTIMATE II, are being conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) and are being led by Lawrence Steinman, MD, of Stanford University.